Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Website: recursion.com



Growth: Bad revenue growth rate -21.4%, there is slowdown compared to average historical growth rates 96.8%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is negative, -735.6%. On average the margin is decreasing steadily. Gross margin is low, -115.6%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.08 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -8.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 93.9% higher than minimum and 78.6% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -31.1x by EV / Sales multiple

Insiders: For the last 3 months insiders sold company shares on $6.5 mln (-0.304% of cap.)

Key Financials (Download financials)

Ticker: RXRX
Share price, USD:  (+0.6%)8.84
year average price 9.04  


year start price 5.16 2023-05-07

max close price 15.86 2023-07-19

min close price 5.09 2023-11-01

current price 8.84 2024-05-06
Common stocks: 223 158 161

Dividend Yield:  0.0%
Last revenue growth (y/y):  -21.4%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  96.8%
Historical growth of EBITDA:  0.0%
EV / Sales: 36.3x
Margin (EBITDA LTM / Revenue): -735.6%
Fundamental value created in LTM:
Market Cap ($m): 1 973
Net Debt ($m): -341
EV (Enterprise Value): 1 632
Price to Book: 4.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-05-03Zacks Investment Research

Recursion Pharmaceuticals (RXRX) Increases Yet Falls Behind Market: What Investors Need to Know

2024-05-02Zacks Investment Research

Recursion Pharmaceuticals, Inc. (RXRX) is Attracting Investor Attention: Here is What You Should Know

2024-04-25Zacks Investment Research

Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors

2024-04-10The Motley Fool

Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.

2024-04-04The Motley Fool

Is This Under-the-Radar Artificial Intelligence (AI) Stock a Buy?

2024-04-03Zacks Investment Research

Down -26.36% in 4 Weeks, Here's Why Recursion Pharmaceuticals (RXRX) Looks Ripe for a Turnaround

2024-04-01Zacks Investment Research

All You Need to Know About Recursion Pharmaceuticals (RXRX) Rating Upgrade to Buy

2024-03-07The Motley Fool

Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street Analyst

2024-03-01GlobeNewsWire

Recursion to Participate in Upcoming Investor Conferences

2024-02-27Seeking Alpha

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2023 Earnings Call Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol RXRX RXRX RXRX RXRX RXRX RXRX
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-29 2023-11-09 2023-08-08 2023-05-08 2023-02-27 2022-11-08
acceptedDate 2024-02-29 08:25:26 2023-11-09 08:08:57 2023-08-08 08:08:07 2023-05-08 08:22:37 2023-02-27 16:44:03 2022-11-08 16:35:39
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 11M 10M 11M 12M 14M 13M
costOfRevenue 23M 11M 9M 12M 11M 15M
grossProfit -13M -775 000 2M -314 000 3M -2M
grossProfitRatio -1.156 -0.077 0.148 -0.026 0.207 -0.180
researchAndDevelopmentExpenses 66M 70M 55M 47M 44M 41M
generalAndAdministrativeExpenses 30M 29M 28M 23M 20M 19M
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 30M 29M 28M 23M 20M 19M
otherExpenses -3M 2M 5M -103 000 3M -107 000
operatingExpenses 97M 99M 83M 70M 64M 60M
costAndExpenses 120M 110M 93M 82M 75M 76M
interestIncome 5M 5M 5M 5M 4M 2M
interestExpense 26 000 25 000 26 000 19 000 13 000 13 000
depreciationAndAmortization 16M 8M 6M 8M 3M 5M
ebitda -94M -85M -82M -62M -61M -57M
ebitdaratio -8.586 -8.455 -7.418 -5.075 -4.459 -4.401
operatingIncome -109M -100M -82M -70M -61M -63M
operatingIncomeRatio -10.020 -9.854 -7.418 -5.758 -4.459 -4.794
totalOtherIncomeExpensesNet 15M 2M 5M 5M 3M 2M
incomeBeforeTax -95M -93M -77M -65M -57M -60M
incomeBeforeTaxRatio -8.688 -9.208 -6.965 -5.384 -4.204 -4.631
incomeTaxExpense -2M 2M -6M -5M -13 000 -2M
netIncome -93M -93M -77M -61M -57M -58M
netIncomeRatio -8.539 -9.208 -6.965 -5.010 -4.203 -4.468
eps -0.400 -0.430 -0.380 -0.320 -0.310 -0.340
epsdiluted -0.400 -0.430 -0.380 -0.320 -0.310 -0.340
weightedAverageShsOut 233M 214M 201M 192M 186M 173M
weightedAverageShsOutDil 233M 214M 201M 192M 186M 173M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol RXRX RXRX RXRX RXRX RXRX RXRX
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-29 2023-11-09 2023-08-08 2023-05-08 2023-02-27 2022-11-08
acceptedDate 2024-02-29 08:25:26 2023-11-09 08:08:57 2023-08-08 08:08:07 2023-05-08 08:22:37 2023-02-27 16:44:03 2022-11-08 16:35:39
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 395M 387M 406M 473M 550M 455M
shortTermInvestments 0 0 0 0 0 0
cashAndShortTermInvestments 395M 387M 406M 473M 550M 455M
netReceivables 3M 3M 3M 2M 3M 12M
inventory 0 2M 3M 1M 1M 0
otherCurrentAssets 40M 18M 19M 16M 16M 13M
totalCurrentAssets 438M 411M 431M 492M 570M 482M
propertyPlantEquipmentNet 120M 120M 125M 125M 121M 120M
goodwill 52M 53M 61M 801 000 801 000 801 000
intangibleAssets 36M 39M 43M 1M 1M 1M
goodwillAndIntangibleAssets 88M 92M 103M 2M 2M 2M
longTermInvestments 7M 8M 8M 0 0 0
taxAssets 36M -8M -8M 0 0 0
otherNonCurrentAssets -36M 8M 8M 8M 8M 8M
totalNonCurrentAssets 216M 220M 236M 135M 131M 130M
otherAssets 1.000 0 0 0 0 0
totalAssets 654M 631M 667M 627M 701M 612M
accountPayables 4M 4M 2M 4M 5M 4M
shortTermDebt 6M 6M 6M 5M 6M 6M
taxPayables 0 0 0 0 0 0
deferredRevenue 36M 44M 73M 58M 57M 47M
otherCurrentLiabilities 47M 40M 33M 25M 33M 27M
totalCurrentLiabilities 93M 94M 114M 92M 100M 83M
longTermDebt 1M 45M 47M 48M 45M 47M
deferredRevenueNonCurrent 51M 51M 32M 57M 70M 94M
deferredTaxLiabilitiesNonCurrent 1M 2M 4M 0 0 0
otherNonCurrentLiabilities 43M 0 0 0 0 84M
totalNonCurrentLiabilities 97M 99M 84M 105M 115M 140M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 43M 50M 51M 51M 50M 52M
totalLiabilities 190M 193M 198M 197M 215M 223M
preferredStock 0.000 0 0 0 0 0
commonStock 2000.000 2000.000 2000.000 2000.000 2000.000 2000.000
retainedEarnings -968M -875M -782M -705M -640M -582M
accumulatedOtherComprehensiveIncomeLoss -0.000 0 0 0 0 0
othertotalStockholdersEquity 1 431M 1 313M 1 251M 1 135M 1 125M 970M
totalStockholdersEquity 463M 438M 469M 430M 486M 388M
totalEquity 463M 438M 469M 430M 486M 388M
totalLiabilitiesAndStockholdersEquity 654M 631M 667M 627M 701M 612M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 654M 631M 667M 627M 701M 612M
totalInvestments 7M 8M 8M 0 0 0
totalDebt 51M 51M 53M 53M 51M 52M
netDebt -344M -336M -353M -420M -499M -402M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol RXRX RXRX RXRX RXRX RXRX RXRX
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-29 2023-11-09 2023-08-08 2023-05-08 2023-02-27 2022-11-08
acceptedDate 2024-02-29 08:25:26 2023-11-09 08:08:57 2023-08-08 08:08:07 2023-05-08 08:22:37 2023-02-27 16:44:03 2022-11-08 16:35:39
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome -93M -93M -77M -65M -57M -60M
depreciationAndAmortization 16M 8M 6M 4M 3M 3M
deferredIncomeTax -54M 19 000 0 0 0 0
stockBasedCompensation 16M 17M 12M 9M 8M 9M
changeInWorkingCapital -11M -4M -10M -24M -601 000 -8M
accountsReceivables -6M -203 000 -814 000 0 0 0
inventory 0 203 000 814 000 0 0 0
accountsPayables -317 000 2M -3M -339 000 695 000 714 000
otherWorkingCapital -5M -7M -8M -24M -1M -8M
otherNonCashItems 53M 170 000 2M 4M 2M 2M
netCashProvidedByOperatingActivities -74M -73M -67M -73M -45M -55M
investmentsInPropertyPlantAndEquipment -2M -827 000 -4M -5M -8M -9M
acquisitionsNet -71 000 0 2M 0 0 0
purchasesOfInvestments 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 480 000 0 0 0 62M
otherInvestingActivites -350 000 398 000 0 0 0 0
netCashUsedForInvestingActivites -2M -347 000 -2M -5M -8M 53M
debtRepayment -694 000 -24 000 -24 000 -24 000 -23 000 -23 000
commonStockIssued 81M 54M 4M 0 144M 0
commonStockRepurchased 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 81M 54M 0 2M 4M 2M
netCashUsedProvidedByFinancingActivities 81M 54M 4M 2M 147M 2M
effectOfForexChangesOnCash 124 000 -115 000 181 000 -2000.000 -307 000 0
netChangeInCash 5M -20M -66M -77M 94M 780 000
cashAtEndOfPeriod 395M 397M 417M 482M 559M 465M
cashAtBeginningOfPeriod 390M 417M 482M 559M 465M 464M
operatingCashFlow -74M -73M -67M -73M -45M -55M
capitalExpenditure -2M -827 000 -4M -5M -8M -9M
freeCashFlow -76M -74M -71M -79M -53M -63M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-27 ET (fiscal 2023 q4)

Press-releases

Show financial reports only

2024-02-27 21:05 ET
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results
2024-02-20 12:59 ET
Recursion to Host Public L(earnings) Call on February 27
2024-01-24 14:00 ET
Altitude Lab Startups Raise Over $120M in Capital
2024-01-08 15:59 ET
Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare Conference
2024-01-04 12:59 ET
Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline
2024-01-04 12:59 ET
Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline
2024-01-03 13:00 ET
Recursion to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
2023-12-20 12:59 ET
Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry
2023-11-09 18:48 ET
Bayer and Recursion focus research collaboration on Oncology
2023-11-09 14:41 ET
Bayer and Recursion Focus Research Collaboration on Oncology
2023-11-09 13:01 ET
Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology
2023-11-09 13:01 ET
Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology
2023-11-09 12:58 ET
Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results
2023-11-02 12:05 ET
Recursion to Participate in Upcoming Investor Conference
2023-09-05 20:30 ET
Recursion to Participate in Upcoming Investor Conferences
2023-09-05 11:59 ET
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
2023-08-08 12:00 ET
Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds
2023-08-08 11:58 ET
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
2023-08-01 12:30 ET
Recursion to Participate in Upcoming Investor Conference
2023-07-26 22:58 ET
Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships
2023-07-12 12:30 ET
Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
2023-07-12 12:30 ET
Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
2023-06-26 15:48 ET
Recursion Celebrates Opening of Its Canadian Headquarters in Toronto with Government Officials and the Biotech Ecosystem
2023-06-13 12:00 ET
Recursion’s Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation has Fully Enrolled
2023-06-01 12:30 ET
Recursion to Participate in Upcoming Investor Conferences
2023-05-25 20:00 ET
Altitude Lab Relocates to Gateway’s BioHive Hub
2023-05-16 12:30 ET
Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer
2023-05-08 12:14 ET
Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results
2023-05-08 11:59 ET
Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities
2023-05-08 11:59 ET
Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities
2023-05-02 12:30 ET
Recursion to Participate in Upcoming Investor Conferences
2023-04-03 12:30 ET
Recursion to Participate in Upcoming Investor Conference
2023-03-28 20:14 ET
Recursion Publishes Second Annual Environmental, Social and Governance Report
2023-03-01 13:00 ET
Recursion to Participate in Upcoming Investor Conferences
2023-02-01 13:01 ET
Recursion to Participate in Upcoming Investor Conference
2023-01-26 13:30 ET
Recursion Releases MolRec, a Compound Intelligence Tool for Drug Discovery, Alongside the Largest of Its Kind Open-Source Dataset During First R&D Day
2022-12-20 12:55 ET
Recursion to Participate in Upcoming Investor Conferences
2022-11-08 21:30 ET
Recursion Provides Business Updates and Reports Third Quarter 2022 Financial Results
2022-11-02 11:59 ET
Recursion to Participate in Upcoming Investor Conferences
2022-10-25 12:00 ET
Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik AB
2022-09-13 11:59 ET
Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022
2022-09-01 11:55 ET
Recursion to Participate in Upcoming Investor Conferences
2022-08-18 11:55 ET
Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum
2022-08-09 20:15 ET
Recursion Provides Business Updates and Reports Second Quarter 2022 Financial Results
2022-08-02 11:55 ET
Recursion to Participate in Upcoming Investor Conference
2022-07-21 11:55 ET
Recursion is Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
2022-06-20 11:55 ET
Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meningiomas at Children's Tumor Foundation NF Conference
2022-06-02 11:55 ET
Recursion to Participate in Upcoming Investor Conferences
2022-05-10 20:29 ET
Recursion Provides Business Updates and Reports First Quarter 2022 Financial Results
2022-05-02 11:55 ET
Recursion to Participate in Upcoming Investor Conference
2022-04-11 11:55 ET
Recursion is Granted Fast Track Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
2022-03-31 11:55 ET
Recursion to Participate in Upcoming Investor Conferences
2022-03-30 11:55 ET
Altitude Lab Announces First Cohort of Startups Close Over $50M in Seed Capital
2022-03-24 11:55 ET
Recursion Publishes First Environmental, Social and Governance (ESG) Report
2022-03-23 11:55 ET
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial Results
2022-03-18 11:55 ET
Recursion Announces Enrollment of First Patient in Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation
2022-03-03 12:55 ET
Recursion Provides Updated Guidance on Clinical Trial Starts
2022-03-02 13:47 ET
Recursion to Participate in Upcoming Investor Conferences
2022-02-08 12:55 ET
Recursion to Participate in Upcoming Investor Conferences
2021-12-07 12:55 ET
Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology, Advancing Novel Medicines to Patients Using Machine Learning and High Content Screening Methods at Scale to Map Complex Biology
2021-12-06 12:55 ET
Recursion and Bayer Expand Fibrosis Collaboration to Include Inferential Search Capabilities
2021-11-30 12:55 ET
Recursion Enhances its Leadership Team and Deepens Focus on Neuroscience with Three Senior Appointments
2021-11-10 12:55 ET
Recursion Provides Business Updates and Reports Third Quarter 2021 Financials
2021-10-07 11:55 ET
Recursion is Granted FDA Fast Track Designation for REC-2282 for the Potential Treatment of NF2-Mutated Meningiomas
2021-09-29 12:54 ET
Recursion is Granted Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
2021-08-13 11:55 ET
Recursion Reports Second Quarter 2021 Financials and Provides Business Updates
2021-07-13 11:55 ET
Recursion Announces Therapeutics Advisory Board, Chaired by Joseph Miletich, MD, PhD
2021-07-12 20:41 ET
Recursion Opens Child Care Center to Support Employees
2021-07-01 12:54 ET
Recursion Signs Lease With Vestar for an Additional 100,000 sf of Space at the Gateway in Downtown Salt Lake City
2021-06-23 12:53 ET
Recursion Announces Multi-Year Collaboration with Mila for Tech-Enabled Drug Discovery
2021-06-15 12:54 ET
Recursion Announces its First Major Multidisciplinary Expansion, in Toronto, to Further Tech-Enabled Drug Discovery
2021-05-25 12:25 ET
Recursion Announces First Internally-Developed NCE Advanced to IND-Enabling Studies to Potentially Treat Clostridium difficile Colitis
2021-05-12 12:45 ET
Recursion Reports First Quarter 2021 Financials and Provides Business Updates
2021-04-21 12:00 ET
Recursion Pharmaceuticals Announces Closing of Initial Public Offering
2021-04-16 04:13 ET
Recursion Pharmaceuticals Announces Pricing of Initial Public Offering

SEC forms

Show financial reports only

SEC form 10
2024-02-29 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q4
SEC form 8
2024-02-27 16:09 ET
Recursion Pharmaceuticals, Inc. reported for 2023 q4
SEC form 8
2024-02-27 16:09 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q4
SEC form 8
2024-02-27 16:09 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q4
SEC form 8
2024-02-27 16:09 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q4
SEC form 10
2023-11-09 08:08 ET
Recursion Pharmaceuticals, Inc. reported for 2023 q3
SEC form 10
2023-11-09 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q3
SEC form 10
2023-08-08 08:08 ET
Recursion Pharmaceuticals, Inc. reported for 2023 q2
SEC form 6
2023-08-08 08:03 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q2
SEC form 6
2023-07-12 08:32 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q2
SEC form 6
2023-06-20 17:09 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q1
SEC form 6
2023-06-13 08:14 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q1
SEC form 8
2023-05-08 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q1
SEC form 10
2023-05-08 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q1
SEC form 6
2023-03-10 16:06 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q4
SEC form 10
2023-02-27 16:44 ET
Recursion Pharmaceuticals, Inc. reported for 2022 q4
SEC form 6
2023-02-27 16:35 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q4
SEC form 10
2023-02-27 00:00 ET
Recursion Pharmaceuticals, Inc. reported for 2022 q4
SEC form 8
2023-02-27 00:00 ET
Recursion Pharmaceuticals, Inc. reported for 2022 q4
SEC form 6
2023-01-25 07:02 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q4
SEC form 6
2023-01-13 17:00 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q4
SEC form 6
2023-01-10 08:01 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q4
SEC form 10
2022-11-08 16:35 ET
Recursion Pharmaceuticals, Inc. reported for 2022 q3
SEC form 6
2022-11-08 16:31 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Recursion Pharmaceuticals, Inc. reported for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Recursion Pharmaceuticals, Inc. reported for 2022 q3
SEC form 6
2022-10-25 08:04 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q3
SEC form 6
2022-09-13 08:01 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q2
SEC form 10
2022-08-09 16:20 ET
Recursion Pharmaceuticals, Inc. reported for 2022 q2
SEC form 6
2022-08-09 16:17 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Recursion Pharmaceuticals, Inc. reported for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Recursion Pharmaceuticals, Inc. reported for 2022 q2
SEC form 6
2022-06-21 08:04 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q1
SEC form 6
2022-06-16 16:31 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q1
SEC form 6
2022-06-09 17:00 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q1
SEC form 10
2022-05-10 16:38 ET
Recursion Pharmaceuticals, Inc. reported for 2022 q1
SEC form 6
2022-05-10 16:34 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q1
SEC form 10
2022-05-10 00:00 ET
Recursion Pharmaceuticals, Inc. reported for 2022 q1
SEC form 8
2022-05-10 00:00 ET
Recursion Pharmaceuticals, Inc. reported for 2022 q1
SEC form 6
2022-04-28 16:01 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q1
SEC form 6
2022-04-11 07:55 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q1
SEC form 10
2022-03-23 08:01 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q4
SEC form 6
2022-03-23 07:56 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q4
SEC form 10
2022-03-23 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q4
SEC form 8
2022-03-23 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q4
SEC form 6
2022-03-18 08:02 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q4
SEC form 6
2022-03-03 07:57 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q4
SEC form 6
2022-01-10 06:20 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q4
SEC form 6
2021-12-07 07:57 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-12-06 07:55 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q3
SEC form 10
2021-11-10 07:57 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-11-10 07:55 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q3
SEC form 10
2021-11-10 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q3
SEC form 8
2021-11-10 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-10-07 08:01 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-09-09 08:01 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q2
SEC form 10
2021-08-13 07:57 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q2
SEC form 6
2021-08-13 07:55 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q2
SEC form 8
2021-08-13 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q2
SEC form 10
2021-08-13 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q2
SEC form 6
2021-07-13 08:18 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q2
SEC form 10
2021-05-12 08:47 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q1
SEC form 6
2021-05-12 08:46 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q1
SEC form 10
2021-05-12 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q1
SEC form 8
2021-05-12 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q1
SEC form 6
2021-04-21 09:08 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q1